ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jan 8, 2018
Nelson: Is Visa the Best Company Ever?
Image Source: Visa’s fiscal fourth-quarter 2017 earnings slide deck. Visa’s business model is phenomenal and its competitive advantages among the best in the world. The company’s free cash flow generation is remarkable, and it alone covers its cash dividend payment by more than 5 times. There are few companies with higher levels of profitability than Visa's, and even fewer that also have as strong of growth potential. The company’s valuation is starting to get a little stretched, but it has the free-cash-flow generation to grow into it.
Jan 7, 2018
Dividend Increases for the Week Ending January 5
Let's take a look at companies raising/lowering their dividends this week.
Jan 6, 2018
Markets Update: January 5, 2018
Image shown: The Dow Jones Industrial Average has performed incredibly since the news of the election of Donald Trump. We’re off to a great start in the New Year. Let’s see how a few newsletter portfolio ideas are performing.
Jan 4, 2018
Intel Facing Selling Pressure Over Security Issue
Image Source: Intel. Dividend Growth and Best Ideas Newsletter idea Intel is facing pressure after reports of a chip flaw surfaced. We’re not overreacting to what may be a transient issue, but we’re monitoring developments like a hawk.
Jan 4, 2018
SMART Global: A Leader in Specialty Memory Solutions
SMART Global is an interesting idea in the memory space, but obsolescence risk and overcapacity will always be two primary concerns. This one is still worth having on your radar.
Jan 2, 2018
The Fed's Dislocation and Too Few Stocks?
President of Investment Research Brian Nelson talks about how central banks may be pushing savers into riskier assets than what might otherwise be warranted by their risk profiles, how interest rates should be viewed within the valuation context, and whether too few stocks to invest in is driving a 'rising tide lifts all boats' dynamic. A discussion about the severe limitations of the price-to-earnings ratio is included. Running time: ~14 minutes.
Jan 2, 2018
2018 Healthcare and Biotech Outlook
Image Source: Global Panorama. 2017 will undoubtedly go down as one of the most fabulous years for the stock market, and while we continue to warn of the dangers associated with the market continuing to trade at lofty valuations, we are intrigued by the outlook for big cap pharma and biotech in the near term. Changes in the US tax laws will likely have a profound impact on the industry.
Dec 30, 2017
Bank Valuations and We're All Market Timers?
President of Investment Research Brian Nelson dives into questions about why an enterprise free cash flow model is not used for banking and insurance entities, and offers up the idea that we all might be market timers. What do you think? Running time: ~14 minutes.
Dec 29, 2017
Valuentum Announcements
We’re excited to usher in the New Year, and we hope you are, too!
Dec 27, 2017
Objectivity in Analysis and the MLP Enigma
President of Investment Research Brian Nelson talks about how financial statement analysis keeps analysts objective. He also goes into how the distribution yields of MLPs may not reflect underlying business dynamics. Nelson also explains an inconsistency in the use of financing that supports the idea that MLPs are using external capital market issuances to fund distributions. Running time: ~15 minutes.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.